Ensysce Biosciences vs Entrada Therapeutics
ENSC and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSC and TRDA compare
Entrada Therapeutics is the larger company, worth 27 times as much as Ensysce Biosciences ($201M against $7.5M).
Ensysce Biosciences grew revenue faster over the last twelve months (37.9% versus −93.5% for Entrada Therapeutics).
Ensysce Biosciences scores higher on the StockData Score (9 against 6 for Entrada Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSC | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $7.5M | $201M |
| Share price | $0.387 | $5.17 |
| Change, 1 year | −81.0% | −32.9% |
| Change, 5 years | −100.0% | −84.2% |
| Beta (5Y) | 2.57 | 0.96 |
| Employees | 8 | 152 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.2× (better) | 50.6× |
| P/B | 0.3× (better) | 1.0× |
| FCF yield | – | −67.7% |
| Fair value | $1.78 | – |
| Margin of safety | 78.2% | – |
| Growth | ||
| Revenue growth (TTM) | 37.9% (better) | −93.5% |
| Revenue growth, 5Y average | 5.2% | – |
| Profitability | ||
| Operating margin | −1477% (better) | −4304% |
| Net margin | – | −4058% |
| FCF margin | – | −3428% |
| Return on equity | – | −59.9% |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −7157.6× | – |
| Current ratio | 8.02 (better) | 7.85 |
| Altman Z-score | −17.64 | −1.62 (better) |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.7% | 75.6% |
| Held by insiders | 6.2% | 14.8% |
| Insider net buying, 12 months | $444K (better) | −$11.5M |
| Short interest, % of float | 0.49% | 8.5% |
Go deeper
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.